US49177J1025 - Common Stock
With a solid technical rating of 8 out of 10, KENVUE INC (NYSE:KVUE) is showing strong indications of a possible breakout.
KVUE earnings call for the period ending September 30, 2024.
Can tinkering around the edges actually make this stock more attractive?
While tech-based growth stocks might seem like the right play, you can't ignore dividends if you want to have a strong portfolio.
Ken Griffin's Citadel just added 18 million shares of an under-the-radar consumer health stock.
An activist investor is taking a stake in Kenvue stock.
The growth rate of the consumer healthcare business could accelerate now that an activist investor is involved.
The activist investor says Pfizer has underperformed its peers and the broader market since 2019.
Pfizer spinoff Kenvue led the S&P 500 on Monday. Nvidia was close behind.
Elf Beauty appeared to rally along with KVUE on Monday.
(Bloomberg) -- Shares of consumer-products company Kenvue Inc. rose the most in two months after activist investor Starboard Value took a stake in the Tylenol maker with an eye toward making changes to boost the company’s stock price.Most Read from BloombergA Broken Oil Pipeline Plunges South Sudan’s Capital Into ChaosDrug Decriminalization Spawns a Political Debacle for ProgressivesClimate Change Is Killing Buildings in Slow MotionCities Look to AI to Flag Residents’ Trash and Recycling Mistake
Target, PepsiCo, and Kenvue have high yields and inexpensive valuations.